KDR and Merkel cell skin cancer: Although limited, data are available on the use of VEGFR-TKIs, and this clinical series correlates prolonged MCC control along with adequate drug tolerance with the use of pazopanib and cabozantinib, reinforcing the hypothesis that TKIs aiming at VEGFs may provide beneficial outcomes in the treatment of disseminated MCC [196].